Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 1/2 data of IMO-8400 for patients with DLBCL who harbor the MYD88 L265P mutation due 2016

Source Link:: http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=2107923

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

IDRA

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details During the third quarter the company continued to enroll patients into the first of three dose cohorts of our Phase 1/2 clinical trial of IMO-8400 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are harboring the MYD88 L265P oncogenic mutation. The company currently anticipates that data from this trial will become available in 2016.

http://ir.iderapharm...

Additional Relevant Details - Driven by Increased Prioritization of IMO-2125 Clinical Development, Company Suspends Development of IMO-8400 for B-Cell Lymphomas –

http://ir.iderapharm...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 26, 2016

Occurred Source:

http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=2205816

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Data, Imo-8400, Dlbcl, Myd88 L265p Mutation